KDR and cancer: Additionally, prior assessment of relevant pharmacodynamic modulation in cancer cell lines demonstrated biochemical kinase selectivity (including inhibition of C-raf, wild-type B-raf, V599E mutant B-raf, VEGFR-2, c-KIT) for sorafenib at an IC50 ranging from 6 to 90 nM (15).